News

A new University of California, Irvine-led study finds a new method for identifying biomarkers may aid in early cancer diagnosis. The study illustrates the importance of considering cell heterogeneity when calculating the DNA methylation level from sequencing data.

In laboratory experiments, plitidepsin, a drug approved for the treatment of multiple myeloma, was 27.5-fold more potent against SARS-CoV-2 than remdesivir. In a seperate preprint, researchers show that plitidepsin also has antiviral activity against the recently identified B.1.1.7 variant.

Breast cancer, even at its initial stages, could be detected earlier and more accurately than current techniques using blood samples and a unique proteomics-based technology, according to findings of a study led by the Translational Genomics Research Institute.

A characteristic feature of all stem cells is their ability to self-renew. But how is this potential maintained throughout life?

In response to inflammation, two enzymes called APOBEC3C and ADAR1 work together to trigger the transformation of pre-cancer stem cells to cancer stem cells in leukemia.

Researchers have discovered that the chemotherapy drug doxorubicin is able to enter heart cells by hitchhiking on a specific type of protein that functions as a transporter to move drugs from the blood into heart cells. By introducing another anti-cancer drug in advance of the chemotherapy, the team was able to block the transporter protein.

Enzymes known as histone deacetylases are targets for a handful of anticancer drugs due to their ability to affect gene expression. Now, researchers have developed a new method to investigate how these enzymes work on a molecular level. This approach could help to identify new anticancer drug candidates quickly.

Researchers have developed an antibody as a biosensor, to continuously monitor rapid changes in the concentration of EGFR, a protein present on cancer cells and in body fluids.

Scientists from UNSW Sydney have developed a ceramic-based ink that may allow surgeons in the future to 3D-print bone parts complete with living cells that could be used to repair damaged bone tissue.

Researchers report that in non-small-cell lung carcinoma, secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable. Combining alectinib with another drug could help to overcome these effects.